Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. - sprookjes - yvandenbroek - TriplyDB

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

http://www.wikidata.org/entity/Q34200348

about

Neuropeptide y and neuropeptide y y5 receptor interaction restores impaired growth potential of aging bone marrow stromal cells Position and length of fatty acids strongly affect receptor selectivity pattern of human pancreatic polypeptide analogues.The neuropeptide y y(1) receptor: a diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts.Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases Ligands of the neuropeptide Y Y2 receptor.Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology Effect of Blocking of Neuropeptide Y Y2 Receptor on Tumor Angiogenesis and Progression in Normal and Diet-Induced Obese C57BL/6 Mice.Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER Platelet neuropeptide Y is critical for ischemic revascularization in mice Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects.Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development.Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R.Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma.A Deep Hydrophobic Binding Cavity is the Main Interaction for Different Y2 R Antagonists.Role of the Nervous System in Tumor Angiogenesis.Prototypic 18F-Labeled Argininamide-Type Neuropeptide Y Y1R Antagonists as Tracers for PET Imaging of Mammary Carcinoma.

P2860

Q28564350-08D42263-532D-4F0B-9E35-9F71A519C2C1 Q33919544-3CAAC7CE-DFC2-4016-9560-261511F051B0 Q34510673-C31B0E68-4BEF-4090-9782-B8D2092444CD Q35097218-6AB49558-8102-41E6-9654-4FDCE4586B7F Q35118454-7EBDF5E6-0D02-4730-AEEA-3381BC5588C5 Q35144928-4514A0B1-2DAF-4544-85AD-27F449BB8276 Q35740170-EBE9D673-A6D7-4C6D-81E2-433E72D3B2D0 Q36355133-A3F6760C-5EE3-499C-9836-8B0D96B458F8 Q36586203-709EBAED-E7DD-456B-8574-6DF746E038C9 Q36718477-1DDDB553-4C33-4BAB-A41D-D0C36D876302 Q36800401-73B6D015-C5EA-44BA-9DB9-DF75F4EDD5D1 Q36860246-88641F17-D104-4DE8-B3B4-30710CB65835 Q37589156-7313ACEA-B6F9-456F-94EB-F01497C634F9 Q37847125-E821D9FB-6E4D-4307-8860-53C94851D48D Q39079841-ED608B8E-5C45-4525-B9F2-4EB5357BDB00 Q39288801-B3B420CC-7E98-4B80-9EE0-E5565E249908 Q40718846-1E560FC3-2217-4CD1-A5D6-CCCBC86CB263 Q48206043-2647A47F-6B3F-4186-BA09-0167A1FE2EE2 Q52675438-CBF0630D-CA0B-4D5D-8BE9-37A7292527EE Q54933533-9E819C05-0F73-4D99-BC3F-540C741E1F40

P2860

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

http://www.wikidata.org/entity/Q34200348

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

@ast

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

@en

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

@nl

type

label

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

@ast

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

@en

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

@nl

prefLabel

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

@ast

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

@en

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

@nl

P1433

Q34200348-4AF2C569-CCE6-4D1A-81DF-9951A2D810E3

P1476

Q34200348-D36FF930-4517-4AF0-9095-F8F53EBE431D

P2093

Q34200348-05A9575C-163E-4692-9709-DF03F96956BC

Q34200348-13ED8672-25BF-45F9-8BF0-55C35F4F596E

Q34200348-1B58F9A6-A0E4-4B3A-A7C1-58272AC8BEE7

Q34200348-5967113F-201C-48A4-9A6F-0B3804E494DE

Q34200348-6107573F-8224-494C-B503-2445B3511350

Q34200348-6CBD64D6-533B-40F2-83DC-722D92548EE8

Q34200348-82B067F5-01D2-435C-93E4-A81C96F5FBAB

Q34200348-9BB38F08-84F3-4C03-A41B-12C6B5DF9484

Q34200348-9D7973B5-3427-4FC9-AB95-F0FF6194DA0C

Q34200348-A1C12E2B-6A81-4D0D-99FD-ECB4F50F7E14

P2860

Q34200348-02AD4E65-6D26-4623-8119-9AB93FE6AEDC

Q34200348-088AA592-4E9B-41F1-8EF9-D128B526DAE5

Q34200348-0CDCCC22-8D30-4EE2-AB11-83E40C9A2F9C

Q34200348-10CDDFED-1E28-4642-B913-45B2171D8DAC

Q34200348-154A142C-5F2B-4E07-A282-3E088BCC3713

Q34200348-318DC632-D335-45A2-9249-F946E6500B08

Q34200348-36B5FBFF-0357-4935-B21B-76FBD3FE0524

Q34200348-3774A05B-E074-4425-8E01-0DA0A8EF640B

Q34200348-3AE91D8D-5807-45E4-9B3F-A26FC18D4D24

Q34200348-439D45DB-9593-41B4-A46A-B04389B94F10

P2888

Q34200348-E0125C94-0061-4BE0-A0D5-EEAA422EC6C1

P304

Q34200348-2379E907-FA41-448F-B547-DCA4FAC5CCFF

P31

Q34200348-580D6AAC-E179-42B1-B850-ECCA3C18A982

P356

Q34200348-75FD0739-C8A1-46EC-A83F-742EF565A870

P407

Q34200348-96D16B2E-AB4A-4625-8A08-832FE8A62338

P433

Q34200348-B187CED9-2713-424A-B9CE-6FE3A8B4CD29

P478

Q34200348-38C89B72-6961-4116-9AE1-6727C619B615

P577

Q34200348-EA2BD7FE-C073-46C3-82A0-ADAC124B3AEB

P5875

Q34200348-1A25F430-341A-4D31-B955-E63A23600DE5

P6179

Q34200348-ECC91917-54EF-4D46-8B2C-4BB07F8D6C75

P698

Q34200348-D2DE4B65-D210-4605-8065-AE497233182B

P932

Q34200348-BF09D7FE-2634-4085-89E9-6450B18E2473

P356

P1433

P1476

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

@en

P2093

A Kuan-Celarier

http://www.w3.org/2001/XMLSchema#string

A-C Jönsson-Rylander

http://www.w3.org/2001/XMLSchema#string

C Lu

http://www.w3.org/2001/XMLSchema#string

C-C J Sun

http://www.w3.org/2001/XMLSchema#string

J A Toretsky

http://www.w3.org/2001/XMLSchema#string

J Kitlinska

http://www.w3.org/2001/XMLSchema#string

J Sun

http://www.w3.org/2001/XMLSchema#string

J Tilan

http://www.w3.org/2001/XMLSchema#string

K Abe

http://www.w3.org/2001/XMLSchema#string

L Everhart

http://www.w3.org/2001/XMLSchema#string

P2860

JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis

Identification of ALK as a major familial neuroblastoma predisposition gene

Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Neuropeptide Y Y1 and neuropeptide Y Y2 receptors in human cardiovascular tissues

Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors

Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones

High expression of neuropeptide y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia

Vascular pharmacology of BIIE0246, the first selective non-peptide neuropeptide Y Y(2) receptor antagonist, in vivo

Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release

Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system

P2888

P304

5630-5642

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2010.301

http://www.w3.org/2001/XMLSchema#string

P407

P433

41

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45440991

http://www.w3.org/2001/XMLSchema#string

P6179

1019235050

http://www.w3.org/2001/XMLSchema#string

P698

20676138

http://www.w3.org/2001/XMLSchema#string

P932

2955165

http://www.w3.org/2001/XMLSchema#string